Gastric adenocarcinoma (progressive stage)
Conditions
Interventions
Group A:Standard D2 gastric carcinoma radical resection+ 800mg Fluorouracil Sustained Release for implant+ Standard Postoperative chemotherapy
Group B:Standard D2 gastric carcinoma radical resection+ Irrigation of peritoneal cavity with 5-FU 500mg/m2+ Standard Postoperative chemotherapy
Sponsors
Ruijin Hospital affiliated to Shanghai Jiaotong University Medical College
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Gastric adenocarcinoma confirmed by pathology. Progressive stage was comfirmed by gastric endoscope or CT or endoscopic ultrasonography; 2. Aged 18-75 years old; 3. Expectant survival >12 months; 4. Blood cell counts results are normal and no severe heart, lung, liver and kidney dysfunction; 5. No jaundice, ascites or GI obstruction; 6. Karnofsky score >=80; 7. Patients who voluntarily signed the informed consent form and agreed to receive standard postoperative adjunctive chemotherapy and follow-up designed by the trial.
Exclusion criteria
Exclusion criteria: 1. The gastric adenocarcinoma is in rapid progression stage; 2. Patients participated in other similar clinical drug trials in last two months since screening; 3. Pregnant or lactated women; 4. Patients have acute infection; 5. Patients with gastric cancer (Early Stage); 6. Patients have severe cardiovascular disease or psychiatric disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor-free survival time;Postoperative survival time; | — |
Countries
China
Contacts
Public ContactZhenggang Zhu
Outcome results
None listed